Filing Flows › Castle Biosciences (CSTL) › Free cash flow
Castle Biosciences (CSTL) free cash flow by quarter
Castle Biosciences' free cash flow was $12.2M in Q3 2026 (third quarter 2026), +87% from Q2 2026. Over the last 5 quarters it ranged from $6.6M (Q2 2026) to $19.7M (Q4 2025).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $12.2M | +87% | +57% |
| Q2 2026 | $6.6M | -67% | -43% |
| Q4 2025 | $19.7M | +153% | — |
| Q3 2025 | $7.8M | -33% | — |
| Q2 2025 | $11.6M | — | — |
Q3 2026 at a glance
Castle Biosciences, Q3 2026: revenue $103M (+24% year over year), operating margin -2.7%, net loss $4.1M, operating cash flow $19.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Castle Biosciences' free cash flow?
Castle Biosciences' free cash flow was $12.2M in Q3 2026 (third quarter 2026), +87% from Q2 2026.
How has Castle Biosciences' free cash flow changed?
Over the last 5 quarters it ranged from $6.6M (Q2 2026) to $19.7M (Q4 2025).